Compass Therapeutics receives Nasdaq notice over minimum bid price deficiency
CMPX•Compass Therapeutics received a Nasdaq deficiency notice on November 19, 2026, after its closing bid remained below $1 for 30 consecutive business days. It has until May 18, 2027, to meet the requirement by closing at or above $1 for at least 10 consecutive business days.
1. Compliance deadline
The notice has no immediate effect on the listing of Compass Therapeutics common stock, which continues to trade on the Nasdaq Capital Market under CMPX. The company has 180 calendar days, until May 18, 2027, to regain compliance; a conditional second 180-day period may be available, and potential remedies include a reverse stock split.




